298 related articles for article (PubMed ID: 28236605)
41. Recent Progress in Understanding the Health Benefits of Curcumin.
Porro C; Panaro MA
Molecules; 2023 Mar; 28(5):. PubMed ID: 36903663
[TBL] [Abstract][Full Text] [Related]
42. Add-on Treatment with Curcumin Has Antidepressive Effects in Thai Patients with Major Depression: Results of a Randomized Double-Blind Placebo-Controlled Study.
Kanchanatawan B; Tangwongchai S; Sughondhabhirom A; Suppapitiporn S; Hemrunrojn S; Carvalho AF; Maes M
Neurotox Res; 2018 Apr; 33(3):621-633. PubMed ID: 29327213
[TBL] [Abstract][Full Text] [Related]
43. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers.
Shoba G; Joy D; Joseph T; Majeed M; Rajendran R; Srinivas PS
Planta Med; 1998 May; 64(4):353-6. PubMed ID: 9619120
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials.
Qin S; Huang L; Gong J; Shen S; Huang J; Ren H; Hu H
Nutr J; 2017 Oct; 16(1):68. PubMed ID: 29020971
[TBL] [Abstract][Full Text] [Related]
45. Curcumin reverses the depressive-like behavior and insulin resistance induced by chronic mild stress.
Shen JD; Wei Y; Li YJ; Qiao JY; Li YC
Metab Brain Dis; 2017 Aug; 32(4):1163-1172. PubMed ID: 28429187
[TBL] [Abstract][Full Text] [Related]
46. Is Really Crocus Sativus as Effective as Citalopram in the Treatment of Depression?
Fountoulakis KN
Pharmacopsychiatry; 2018 May; 51(3):105. PubMed ID: 28351080
[No Abstract] [Full Text] [Related]
47. Saffron in the treatment of depression, anxiety and other mental disorders: Current evidence and potential mechanisms of action.
Shafiee M; Arekhi S; Omranzadeh A; Sahebkar A
J Affect Disord; 2018 Feb; 227():330-337. PubMed ID: 29136602
[TBL] [Abstract][Full Text] [Related]
48. Investigation of the Anxiolytic and Antidepressant Effects of Curcumin, a Compound From Turmeric (Curcuma longa), in the Adult Male Sprague-Dawley Rat.
Ceremuga TE; Helmrick K; Kufahl Z; Kelley J; Keller B; Philippe F; Golder J; Padrón G
Holist Nurs Pract; 2017; 31(3):193-203. PubMed ID: 28406873
[TBL] [Abstract][Full Text] [Related]
49. Curcumin for depression: a meta-analysis.
Fusar-Poli L; Vozza L; Gabbiadini A; Vanella A; Concas I; Tinacci S; Petralia A; Signorelli MS; Aguglia E
Crit Rev Food Sci Nutr; 2020; 60(15):2643-2653. PubMed ID: 31423805
[TBL] [Abstract][Full Text] [Related]
50. A meta-analysis of the use of probiotics to alleviate depressive symptoms.
Ng QX; Peters C; Ho CYX; Lim DY; Yeo WS
J Affect Disord; 2018 Mar; 228():13-19. PubMed ID: 29197739
[TBL] [Abstract][Full Text] [Related]
51. l-Theanine and caffeine improve target-specific attention to visual stimuli by decreasing mind wandering: a human functional magnetic resonance imaging study.
Kahathuduwa CN; Dhanasekara CS; Chin SH; Davis T; Weerasinghe VS; Dassanayake TL; Binks M
Nutr Res; 2018 Jan; 49():67-78. PubMed ID: 29420994
[TBL] [Abstract][Full Text] [Related]
52. Curcumin or combined curcuminoids are effective in lowering the fasting blood glucose concentrations of individuals with dysglycemia: Systematic review and meta-analysis of randomized controlled trials.
de Melo ISV; Dos Santos AF; Bueno NB
Pharmacol Res; 2018 Feb; 128():137-144. PubMed ID: 28928074
[TBL] [Abstract][Full Text] [Related]
53. affron
Kell G; Rao A; Beccaria G; Clayton P; Inarejos-García AM; Prodanov M
Complement Ther Med; 2017 Aug; 33():58-64. PubMed ID: 28735826
[TBL] [Abstract][Full Text] [Related]
54. Effects of curcumin consumption on human chronic diseases: A narrative review of the most recent clinical data.
Mantzorou M; Pavlidou E; Vasios G; Tsagalioti E; Giaginis C
Phytother Res; 2018 Jun; 32(6):957-975. PubMed ID: 29468820
[TBL] [Abstract][Full Text] [Related]
55. Curcumin: A Review of Its Effects on Human Health.
Hewlings SJ; Kalman DS
Foods; 2017 Oct; 6(10):. PubMed ID: 29065496
[TBL] [Abstract][Full Text] [Related]
56. A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS).
Ng QX; Soh AYS; Loke W; Venkatanarayanan N; Lim DY; Yeo WS
J Clin Med; 2018 Sep; 7(10):. PubMed ID: 30248988
[TBL] [Abstract][Full Text] [Related]
57. Cognitive deficits in individuals with methamphetamine use disorder: A meta-analysis.
Potvin S; Pelletier J; Grot S; Hébert C; Barr AM; Lecomte T
Addict Behav; 2018 May; 80():154-160. PubMed ID: 29407687
[TBL] [Abstract][Full Text] [Related]
58. Curcumin Acts as a Positive Allosteric Modulator of
El Nebrisi EG; Bagdas D; Toma W; Al Samri H; Brodzik A; Alkhlaif Y; Yang KS; Howarth FC; Damaj IM; Oz M
J Pharmacol Exp Ther; 2018 Apr; 365(1):190-200. PubMed ID: 29339457
[TBL] [Abstract][Full Text] [Related]
59. One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis.
Takeuchi H; Kantor N; Sanches M; Fervaha G; Agid O; Remington G
Br J Psychiatry; 2017 Sep; 211(3):137-143. PubMed ID: 28522434
[No Abstract] [Full Text] [Related]
60. A Systematic Review of the Clinimetric Properties of the 6-Item Version of the Hamilton Depression Rating Scale (HAM-D6).
Timmerby N; Andersen JH; Søndergaard S; Østergaard SD; Bech P
Psychother Psychosom; 2017; 86(3):141-149. PubMed ID: 28490031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
